PT-141: Bremelanotide Research Guide

Palmetto Peptides Research Team

February 22, 2026

peptidespt-141researchsexual-health

PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist developed from Melanotan II (MT-2) research. While MT-2 is a broad-spectrum melanocortin agonist with effects across MC1R through MC5R, PT-141 emerged from the observation that MT-2 metabolites retained meaningful pharmacological activity — specifically at MC4R, which mediates sexual arousal and function. PT-141 (the carboxylic acid metabolite of MT-2) subsequently underwent clinical development that culminated in FDA approval in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it the only FDA-approved melanocortin receptor agonist for sexual function.

Development and Structural Context

The path from MT-2 to PT-141 illustrates how broad-spectrum pharmacological research leads to selective therapeutic development. MT-2 was originally developed at the University of Arizona as a potential tanning peptide targeting MC1R. During Phase I human trials, researchers observed potent sexual arousal effects as a prominent side effect — subsequently attributed to MC4R activation in the hypothalamus. Metabolic studies identified PT-141 as MT-2's primary active metabolite (formed by removal of the N-terminal acetyl group), retaining MC4R activity with a modified receptor binding profile.

PT-141's structure (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 with the N-terminal deacetylated) preserves the cyclic lactam scaffold and D-amino acid substitutions that confer metabolic stability. It has a plasma half-life of approximately 2.7 hours — sufficient for meaningful receptor engagement following subcutaneous or intranasal administration.

Mechanism of Action

MC4R Agonism and Sexual Function

MC4R is expressed in the paraventricular nucleus (PVN) of the hypothalamus and other brain regions involved in sexual behavior, appetite, and autonomic function. Research establishing the central role of MC4R in sexual arousal used MC4R knockout mouse models — animals that fail to show the pro-erectile and sexual arousal responses observed with melanocortin agonist administration. Key mechanistic findings:

MC4R activation in the PVN initiates downstream signaling that increases activity in pathways involved in erectile function and sexual arousal in both male and female models
PT-141 appears to activate central (hypothalamic) sexual arousal circuits rather than peripheral vascular mechanisms — distinguishing it mechanistically from PDE5 inhibitors (sildenafil, tadalafil) which act on penile vasculature
MC4R agonism appears to stimulate dopamine release in mesolimbic pathways associated with sexual motivation, consistent with observed increases in sexual desire rather than purely mechanical/vascular effects

Mechanism vs. PDE5 Inhibitors

The mechanistic distinction between PT-141 and PDE5 inhibitors is clinically and scientifically important. PDE5 inhibitors (sildenafil, tadalafil) work peripherally — enhancing nitric oxide-mediated vasodilation in erectile tissue. They are effective for vascular-cause erectile dysfunction but do not address central desire and arousal components. PT-141 acts centrally — activating hypothalamic sexual arousal circuits and apparently increasing sexual motivation and desire. Research has examined PT-141 in subjects who failed PDE5 inhibitor therapy, finding response in some non-responders — consistent with addressing different mechanistic pathways.

Key Research Findings

Male Sexual Dysfunction Research

Early Phase I/II research in male subjects demonstrated PT-141's ability to induce penile erections — including in men with psychogenic and organic erectile dysfunction. The central mechanism appeared to offer benefit for subjects in whom psychological factors or central arousal deficits contributed to dysfunction. Research also documented effects on sexual desire (libido) as distinct from mechanical erection — an important distinction for research into the multidimensional biology of male sexual function.

Female HSDD Research

PT-141 underwent Phase III clinical development for female HSDD — a condition characterized by diminished sexual desire causing personal distress. The RECONNECT trials examined PT-141 administered via subcutaneous autoinjector on an as-needed basis. FDA approval (2019, Vyleesi) was based on statistically significant improvements in satisfying sexual events and desire scores versus placebo, with an acceptable safety profile. The primary side effects were transient nausea, flushing, and injection site reactions — consistent with the pharmacological profile of melanocortin receptor activation and sympathetic nervous system effects.

Melanocortin Receptor Selectivity Research

A research area of ongoing interest is PT-141's receptor selectivity profile relative to MT-2. PT-141 shows meaningful activity at MC1R, MC3R, MC4R, and MC5R — like MT-2 — but with altered relative potencies. The sexual effects are primarily MC4R-mediated (confirmed by MC4R knockout models), while pigmentation effects (MC1R) and cardiovascular effects observed at higher doses reflect the multi-receptor profile. Researchers studying melanocortin receptor biology use PT-141 alongside MT-2 to probe receptor-specific contributions to observed effects.

Research Protocols

PT-141 is reconstituted from lyophilized powder in bacteriostatic water for subcutaneous administration in research settings. Intranasal administration has also been studied — with lower bioavailability but potentially faster onset. Storage follows standard lyophilized peptide protocols: refrigeration after reconstitution, protection from light, avoidance of freeze-thaw cycling. Given the central nervous system effects, behavioral outcome measures are key endpoints in animal research.

Frequently Asked Questions

How does PT-141 differ from its parent compound MT-2?

PT-141 is a structural derivative of MT-2 (MT-2 metabolite missing the N-terminal acetyl group). Both share the cyclic structure but differ in receptor potency profile. MT-2 was developed primarily for MC1R-mediated melanogenesis; PT-141 emerged from the observation that MT-2 metabolites retained the MC4R sexual arousal activity that became PT-141's primary research and clinical focus.

What distinguishes PT-141's mechanism from testosterone therapy in sexual dysfunction?

Testosterone primarily acts through androgen receptors in peripheral tissues and the brain, supporting physiological maintenance of libido, erectile function, and secondary sexual characteristics. PT-141 acutely activates central MC4R circuits involved in sexual arousal and motivation — a faster-acting, receptor-specific mechanism distinct from the broad androgenic effects of testosterone.

Is PT-141 research relevant to neuropsychiatric applications beyond sexual function?

MC4R is expressed broadly in the hypothalamus and limbic system, with roles in appetite regulation, stress response, and anxiety in addition to sexual function. Research examining PT-141 and related MC4R agonists has produced data relevant to these broader neural systems — though sexual function has been the primary clinical development focus. The POMC/melanocortin system's breadth makes PT-141 a useful research tool for central melanocortin receptor biology beyond its approved indication.

References

Diamond LE, et al. (2004). A double-blind, placebo-controlled evaluation of the safety, pharmacological properties and exercise tolerance of intranasal PT-141. Journal of Sexual Medicine. PMID: 16422870
Safarinejad MR. (2008). Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder. Journal of Sexual Medicine. PMID: 18266988
Mountjoy KG. (2010). Functions for pro-opiomelanocortin-derived peptides in obesity and diabetes. Biochemical Journal. PMID: 20795951

Disclaimer: All compounds offered by Palmetto Peptides are strictly for laboratory research and in vitro studies. They are not intended for human consumption, veterinary use, or any therapeutic application. All information provided is for educational and scientific reference only. Palmetto Peptides makes no health claims. Consult a licensed medical professional before handling any research compound.